Cygenics contract with DOD renewed

By Melissa Trudinger
Wednesday, 16 February, 2005

Singapore-based Cygenics (ASX: CYN) has announced that the US Department of Defence had renewed its screening service contract with the company's US-based subsidiary Cytomatrix.

The renewal of the contract means that the company will receive the more than US$1 million remaining from the original contract which was valued at $1.684 million.

The DOD is using Cytomatrix's three-dimensional cell growth scaffold technology for the production of T cells that can be used to screen vaccine prototypes under development, allowing assessment of in vivo activity in an in vitro system.

Related News

Immune cell boost could enable lasting vaccine protection

A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...

Genes influence when babies start walking

Genetics accounts for about a quarter of the differences in when children take their first steps,...

Novel glycopeptide antibiotic candidate shows promise

Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd